157 related articles for article (PubMed ID: 35428910)
41. CD160 protein as a new therapeutic target in a battle against autoimmune, infectious and lifestyle diseases. Analysis of the structure, interactions and functions.
Piotrowska M; Spodzieja M; Kuncewicz K; Rodziewicz-Motowidło S; Orlikowska M
Eur J Med Chem; 2021 Nov; 224():113694. PubMed ID: 34273660
[TBL] [Abstract][Full Text] [Related]
42. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.
Muscate F; Stetter N; Schramm C; Schulze Zur Wiesch J; Bosurgi L; Jacobs T
Front Immunol; 2018; 9():2611. PubMed ID: 30483269
[TBL] [Abstract][Full Text] [Related]
43. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
44. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
45. SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.
Loria R; Laquintana V; Scalera S; Fraioli R; Caprara V; Falcone I; Bazzichetto C; Di Martile M; Rosanò L; Del Bufalo D; Bossi G; Sperduti I; Terrenato I; Visca P; Soddu S; Milella M; Ciliberto G; Falcioni R; Ferraresi V; Bon G
J Exp Clin Cancer Res; 2022 Apr; 41(1):148. PubMed ID: 35440004
[TBL] [Abstract][Full Text] [Related]
46. The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function.
Rey J; Giustiniani J; Mallet F; Schiavon V; Boumsell L; Bensussan A; Olive D; Costello RT
Eur J Immunol; 2006 Sep; 36(9):2359-66. PubMed ID: 16917959
[TBL] [Abstract][Full Text] [Related]
47. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells.
Fons P; Chabot S; Cartwright JE; Lenfant F; L'Faqihi F; Giustiniani J; Herault JP; Gueguen G; Bono F; Savi P; Aguerre-Girr M; Fournel S; Malecaze F; Bensussan A; Plouët J; Le Bouteiller P
Blood; 2006 Oct; 108(8):2608-15. PubMed ID: 16809620
[TBL] [Abstract][Full Text] [Related]
48. The density and spatial tissue distribution of CD8
Massi D; Rulli E; Cossa M; Valeri B; Rodolfo M; Merelli B; De Logu F; Nassini R; Del Vecchio M; Di Guardo L; De Penni R; Guida M; Sileni VC; Di Giacomo AM; Tucci M; Occelli M; Portelli F; Vallacchi V; Consoli F; Quaglino P; Queirolo P; Baroni G; Carnevale-Schianca F; Cattaneo L; Minisini A; Palmieri G; Rivoltini L; Mandalà M;
J Immunother Cancer; 2019 Nov; 7(1):308. PubMed ID: 31730502
[TBL] [Abstract][Full Text] [Related]
49. Engagement of the CD160 activating NK cell receptor leads to its association with CD2 in circulating human NK cells.
Rabot M; Bensussan A; Le Bouteiller P
Transpl Immunol; 2006 Dec; 17(1):36-8. PubMed ID: 17157212
[TBL] [Abstract][Full Text] [Related]
50. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.
Le Bouteiller P; Barakonyi A; Giustiniani J; Lenfant F; Marie-Cardine A; Aguerre-Girr M; Rabot M; Hilgert I; Mami-Chouaib F; Tabiasco J; Boumsell L; Bensussan A
Proc Natl Acad Sci U S A; 2002 Dec; 99(26):16963-8. PubMed ID: 12486241
[TBL] [Abstract][Full Text] [Related]
51. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Devji T; Levine O; Neupane B; Beyene J; Xie F
JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
[TBL] [Abstract][Full Text] [Related]
52. Characterization of murine CD160+ CD8+ T lymphocytes.
Tsujimura K; Obata Y; Matsudaira Y; Nishida K; Akatsuka Y; Ito Y; Demachi-Okamura A; Kuzushima K; Takahashi T
Immunol Lett; 2006 Jul; 106(1):48-56. PubMed ID: 16764942
[TBL] [Abstract][Full Text] [Related]
53. CD160 Stimulates CD8
Tan CL; Peluso MJ; Drijvers JM; Mera CM; Grande SM; Brown KE; Godec J; Freeman GJ; Sharpe AH
Immunohorizons; 2018 Aug; 2(7):238-250. PubMed ID: 31022694
[TBL] [Abstract][Full Text] [Related]
54. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
55. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
56. BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody.
Sanlorenzo M; Vujic I; Floris A; Novelli M; Gammaitoni L; Giraudo L; Macagno M; Leuci V; Rotolo R; Donini C; Basiricò M; Quaglino P; Fierro MT; Giordano S; Sibilia M; Carnevale-Schianca F; Aglietta M; Sangiolo D
Clin Cancer Res; 2018 Jul; 24(14):3377-3385. PubMed ID: 29650750
[No Abstract] [Full Text] [Related]
57. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
[TBL] [Abstract][Full Text] [Related]
58. CD160 Plays a Protective Role During Chronic Infection by Enhancing Both Functionalities and Proliferative Capacity of CD8+ T Cells.
Zhang L; Zhang A; Xu J; Qiu C; Zhu L; Qiu C; Fu W; Wang Y; Ye L; Fu YX; Zhao C; Zhang X; Xu J
Front Immunol; 2020; 11():2188. PubMed ID: 33072082
[TBL] [Abstract][Full Text] [Related]
59. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
60. CD160 serves as a negative regulator of NKT cells in acute hepatic injury.
Kim TJ; Park G; Kim J; Lim SA; Kim J; Im K; Shin MH; Fu YX; Del Rio ML; Rodriguez-Barbosa JI; Yee C; Suh KS; Kim SJ; Ha SJ; Lee KM
Nat Commun; 2019 Jul; 10(1):3258. PubMed ID: 31332204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
